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routine EPI vaccinations including Oral Polio Vaccine(OPV)
to healthy infants in a phase III, double-blind, ran-
domized, placebo-controlled and multi-center study
(444563/024/NCT00139347) conducted in six countries
in Latin-America is presented.Methods: Healthy infants
aged 6-12 weeks were enrolled to receive two doses of
RIX4414(N = 4376) or placebo(N = 2192) according to a 0,1—2
month schedule, administered concomitantly with Dose 1
and Dose 2 of routine pediatric vaccines including OPV, given
respecting the national immunisation guidelines.Vaccine
efﬁcacy(VE) was calculated from two weeks post-Dose2
until one year of age. Severe GE was deﬁned as an episode
of diarrhea requiring hospitalization and/or re-hydration
therapy in a medical facility. Diarrhoeal samples were ana-
lyzed for RV by ELISA and typed by RT-PCR based method.
Safety data were collected throughout the study.
Results: During the efﬁcacy follow-up period (mean
duration of 7.4 months) RIX4414 has offered 81.6%
(95%CI:54.4;93.5) protection against severe RVGE and 88.3%
(95%CI:64.0;97.1) against hospitalization due to RVGE.
For severe RVGE, VE against wild-type G1 was 100%
(95%CI:<0;100) and 80.6% (95%CI:51.4;93.2) against pooled
non-G1 RV types (G2,G9). No clinically meaningful differ-
ence between RIX4414 group and the placebo group for
serious adverse events were reported.
Conclusion: Two doses of RIX4414(RotarixTM)offer high
protection against severe RVGE and related hospitaliza-
tions when co-administered with speciﬁc childhood vaccines
including OPV. These results show that co-administration
with OPV does not impact the efﬁcacy of RotarixTM and are
in line with the high efﬁcacy against severe RVGE of 85%
demonstrated in a large Phase III Latin America study with
staggered co-administration of OPV. This ﬁnding is of signiﬁ-
cance for the implementation of RV vaccination programmes
in many countries where OPV is still routinely administered.
doi:10.1016/j.ijid.2008.05.367
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Background: The lyophilized formulation of Glaxo-
SmithKline’s oral, live attenuated human rotavirus vaccine
RIX4414(RotarixTM) has shown to be immunogenic in vari-
ous phase III trials in Europe and Latin America. A phase III,
open-label, randomized, study(107077/NCT00363545) was
conducted in Panama to assess the immunogenicity of two
doses of RIX4414 oral suspension (liquid formulation) to
that of the lyophilised formulation with routine vaccinations
given concomitantly.
Methods: Healthy infants, 6—12 weeks old (N = 1274)
were enrolled to receive two doses of RIX4414 oral
suspension(RIX4414-liq) or RIX4414 lyophilized(RIX4414-lyo)
according to a 0,2 month schedule. Routine vaccina-
tions (oral poliovirus vaccines(OPV), DTPw-HBV/Hib) were
administered concurrently following local EPI schedule.
Anti-rotavirus IgA antibody concentrations were assessed at
pre-vaccination and 1 to 2 months post-Dose 2 (ELISA, cut-
off ≥20U/mL). The anti-rotavirus IgA seroconversion rates
and corresponding Geometric Mean Concentrations(GMCs)
were calculated. Solicited symptoms (fever, diarrhoea, irri-
tability, cough/runny nose, loss of appetite, vomiting) were
collected for 15-days after each dose, unsolicited symp-
toms 31-days after each dose. Safety data were collected
throughout the study.
Results: The two RIX4414-liq and RIX4414-lyo groups
had a similar demographic proﬁle. Anti-rotavirus IgA sero-
conversion rates at 1 to 2 months post-Dose2 was 80.8%
(95%CI: 76.9%;84.4%) in the RIX4414-liq group(n = 449)
and was 73.5%(95%CI:69.1%;77.6%) in the RIX4414-lyo
group(n = 434). GMCs calculated in seropositive infants was
287.8U/mL (95%CI:250.2;331.2) in the RIX4414-liq group
and 266.6U/mL (95%CI:228.6;310.8) in the RIX4414-lyo
group. The reactogenicity proﬁle of the RIX4414-liq group
was similar to the RIX4414-lyo group. No vaccination related
serious adverse events.
Conclusion: This study indicates that both formulations
of RIX4414(RotarixTM) elicited a good immune response 1
to 2 months post-Dose2 when co-administered with rou-
tine childhood vaccines. This is of importance in considering
the implementation of rotavirus UMV programmes. The two
formulations were well tolerated with no clinical concerns
raised based on the available safety data.
doi:10.1016/j.ijid.2008.05.368
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Background: Measels cases began to decline in 1990 in
Taiwan just after a 5 year period in which 3 large out-
breaks occurred with one to two thousand cases in the 1980’s
(1985:2219 cases, 97 fatal; 1988: 1386 cases; 1989: 1060
cases, 12 fatal). Since 2003 less than 10 measles cases have
been conﬁrmed annually.
Methods: Specimens including throat swabs, urine, or
sera were collected from 67 patients with serological con-
ﬁrmed infection during the period of 1992—2007. B95a cell
lines were used for virus isolation. After measles virus (MV)
identiﬁcation by immunoﬂuorescence, virus gene targets (N,
nucleoprotein and H, hemagglutinin) were ampliﬁed (RT-
PCR), sequenced and compared to reference sequences.
Results: After diagnostic tests the 67 isolates were
assigned to the following 7 genotypes: A (4), D3 (5), D5 (8),
D9 (2), G2 (3), H1 (42), and H2 (3). The genotype H1 strains
were responsible for cases in 1992 and outbreaks in 1994
and 2002. Most of the genotype H1 cases after 2001 were
derived from China. Epidemiological information showed 16
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(of 18) imported MV strains between 2003-2007. Additional
information is needed to track strains prior to 2000.
Conclusions: Seven genotypes (A, D3, D5, D9, G2, H1
and H2) were recognized from MV cases during 1992-2007.
Viruses of genotype H1 and D3 are implicated as indigenous
strains in Taiwan. In Taiwan, one-dose measles immunization
program began in 1978, and two-dose policy started in 1984.
Two catch-up campaigns were implemented in 1992—1994
and 2002—2004 separately. The vaccine coverage rate with
1st dose MV (for 12—15 months) and 2nd dose MMR (for
6 years old) was over 90% and 95% since 1996. The mul-
tiple genotypes and sporadic cases discovered after 2003
(except 2 cases in 2005) were all imported. The measles
mass vaccination program has successfully interrupted the
transmission of indigenous MV in Taiwan.
doi:10.1016/j.ijid.2008.05.369
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Background and Aim: The GlaxoSmithKline oral human
attenuated rotavirus (RV) vaccine RIX4414 (RotarixTM) has
been shown to be highly effective for the prevention of
RV gastroenteritis (GE) globally. Infants participating in a
double-blind, randomized, placebo-controlled and multi-
centre trial conducted in Singapore, Hong Kong and Taiwan
(e-track107070,107072,107076/NCT444563/028/029/030)
were followed up to approximately two years of age to
assess protection against severe RVGE.
Methods: 10708 healthy infants, 6—17 weeks of age at
Dose 1 were enrolled and randomised into two groups (1:1)
to receive 2 doses of RIX4414 vaccine or placebo at a 0,1-2
month schedule. Routine vaccinations were given concomi-
tantly. Vaccine efﬁcacy (VE) was calculated from 2-weeks
post-Dose2 until approximately 24months of age. Severity of
RVGE was assessed using the 20-point Vesikari scale (severe
RVGE ≥11). Diarrhoeal stool samples were analyzed for RV
by ELISA and typed by RT-PCR based method. Safety data
was collected throughout the study.
Results: During the efﬁcacy follow-up period (mean dura-
tion of 20 months), 2 severe RVGE episodes were reported in
RIX4414 and 51 in the placebo group. VE against severe RVGE
was 96.1% (95%CI:85.1;99.5), 100.0% (95%CI:80.8;100.0)
against wild-type G1 and 93.6% (95%CI:74.7;99.3) against
pooled non-G1 RV types(G2,G3,G9) proving broad pro-
tection by RIX4414. Efﬁcacy against hospitalized RVGE
was 93.8% (95%CI:80.6;98.8). An overall reduction of
29.2%(95%CI:12.9;42.5) of hospitalization due to all cause
GE episode was observed compared to placebo. There was
no clinically meaningful difference between RIX4414 group
and the placebo group for SAEs reported during the study.
Conclusions: Presented results demonstrate that in an
Asian urban setting, two oral doses of RIX4414 (RotarixTM)
offer high and sustained protection against severe RVGE dur-
ing the ﬁrst two years of life when the disease burden is
highest. These data are in line with efﬁcacy results obtained
for RotarixTM in Europe.
doi:10.1016/j.ijid.2008.05.370
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Background: 6—12 week-old healthy infants were ran-
domized to receive 3 oral doses of the pentavalent rotavirus
vaccine (PRV), RotaTeqTM, or placebo in the Rotavirus Efﬁ-
cacy and Safety Trial (REST). To determine if PRV remains
efﬁcacious beyond 2 years after vaccination, approximately
21,000 REST infants in the safety cohort in Finland were fol-
lowed for healthcare resource utilization (HCRU), deﬁned
as rotavirus gastroenteritis (RGE)-associated hospitaliza-
tions and/or emergency department (ED) visits, in a Finnish
Extension Study (FES) for up to 3.1 years after completing
vaccination.
Methods: FES infants were contacted every 12 weeks to
determine whether they had any RGE-related HCRU. RGE
was deﬁned as forceful vomiting and/or ≥3 watery or looser-
than-normal stool within a 24-hour period and detection of
rotavirus antigen by enzyme immunoassay, plaque assay, and
PCR assays to determine the P and G types. Infants with RGE,
who received 3 vaccine doses, were included in the analysis,
and follow-up started 14 days after dose 3.
Results: The maximum follow-up time in REST was 2 years
(730.5 days) and in REST and FES was 3.1 years (1126 days).
Overall, PRV reduced the rate of RGE-associated HCRU,
regardless of rotavirus serotype, by 94% (95% conﬁdence
interval [CI]: 91.3, 95.9) for up to 3.1 years after the third
dose, demonstrating an overall reduction of HCRU similar to
that of REST (95% [95% CI: 91.5, 96.5]).
Conclusion: RGE-associated HCRU continues to be com-
mon in the second year of life but decreases in the third year
of life. PRV signiﬁcantly reduced RGE-associated hospitaliza-
tions and ED visits among FES infants, regardless of serotype,
for up to 3.1 years of follow-up after completing vaccina-
tion. The results of FES are consistent with the results of
REST and conﬁrm that the efﬁcacy of PRV remains consis-
tent beyond two years, and up to 3.1 years, after completing
vaccination.
doi:10.1016/j.ijid.2008.05.371
